MHRA (UK) approves seladelpar (Livdelzi) to treat primary biliary cholangitis – CymaBay
The Medicines and Healthcare products Regulatory Agency (MHRA) (UK) has 16 January 2025, approved the medicine seladelpar (Livdelzi) in adults for the treatment of a liver illness called… read more.